Therefore, we believe that our findings provide an important layer in Cfl2 regulation, which needs further in vivo validations for exploiting the therapeutic potential of miR-301/Cfl2 interactions in cardiac signal transduction and DCM. The gene discussed is CFL2; the disease is familial dilated cardiomyopathy.